Abstract
CTLA-4 is a negative regulator of the proliferation and the effector function of T-cells. Therefore, it might be important to determine its expression on tumor cells and T-lymphocytes from cancer patients, to investigate its role in initiating and maintaining the neoplastic pathogenesis. CTLA-4 expression was detected in breast tissue by immunohistochemical staining and RT-PCR in 60 patients with breast cancer and 30 normal controls. The levels of CTLA-4 on T lymphocytes in 33 of the patients and 27 of the control group were determined by flow cytometry. Isolated peripheral blood mononuclear cells (PBMCs) were stimulated with phytohaemagglutinin (PHA). Stimulation index and IL-2 level in the cell culture supernatant were measured by MTT assay and ELISA method, respectively. Patients showed strong expression of CTLA-4 in the tumor cells of all specimens at both the protein and mRNA level, but only weakly positive or negative expression in normal breast tissue. Patients with higher mRNA level of CTLA-4 had obvious axillary lymph nodes metastases and higher clinical stage. Spontaneous expression of CD3+CTLA-4+ on PBMCs of tumor patients was also significantly higher than that of the controls. Moreover, PBMCs derived from patients with high expression of CD3+CTLA-4+ T-cells showed poor responsiveness to PHA stimulation and lower IL-2 production. Therefore, abnormal expression and dysregulation of CTLA-4 could partly explain the mechanism of evasion of anti-tumor immune responses in breast cancer patients and therefore highlight its importance in the development and progression of breast cancer.
Keywords: Breast cancer, CTLA-4, CD152, PBMC, flow cytometry, dysregulation, stimulation index, IL-2.
Current Cancer Drug Targets
Title:New Insights of CTLA-4 into Its Biological Function in Breast Cancer
Volume: 10 Issue: 7
Author(s): H. Mao, L. Zhang, Y. Yang, W. Zuo, Y. Bi, W. Gao, B. Deng, J. Sun, Q. Shao and X. Qu
Affiliation:
Keywords: Breast cancer, CTLA-4, CD152, PBMC, flow cytometry, dysregulation, stimulation index, IL-2.
Abstract: CTLA-4 is a negative regulator of the proliferation and the effector function of T-cells. Therefore, it might be important to determine its expression on tumor cells and T-lymphocytes from cancer patients, to investigate its role in initiating and maintaining the neoplastic pathogenesis. CTLA-4 expression was detected in breast tissue by immunohistochemical staining and RT-PCR in 60 patients with breast cancer and 30 normal controls. The levels of CTLA-4 on T lymphocytes in 33 of the patients and 27 of the control group were determined by flow cytometry. Isolated peripheral blood mononuclear cells (PBMCs) were stimulated with phytohaemagglutinin (PHA). Stimulation index and IL-2 level in the cell culture supernatant were measured by MTT assay and ELISA method, respectively. Patients showed strong expression of CTLA-4 in the tumor cells of all specimens at both the protein and mRNA level, but only weakly positive or negative expression in normal breast tissue. Patients with higher mRNA level of CTLA-4 had obvious axillary lymph nodes metastases and higher clinical stage. Spontaneous expression of CD3+CTLA-4+ on PBMCs of tumor patients was also significantly higher than that of the controls. Moreover, PBMCs derived from patients with high expression of CD3+CTLA-4+ T-cells showed poor responsiveness to PHA stimulation and lower IL-2 production. Therefore, abnormal expression and dysregulation of CTLA-4 could partly explain the mechanism of evasion of anti-tumor immune responses in breast cancer patients and therefore highlight its importance in the development and progression of breast cancer.
Export Options
About this article
Cite this article as:
Mao H., Zhang L., Yang Y., Zuo W., Bi Y., Gao W., Deng B., Sun J., Shao Q. and Qu X., New Insights of CTLA-4 into Its Biological Function in Breast Cancer, Current Cancer Drug Targets 2010; 10 (7) . https://dx.doi.org/10.2174/156800910793605811
DOI https://dx.doi.org/10.2174/156800910793605811 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Snake Venom: From Deadly Toxins to Life-saving Therapeutics
Current Medicinal Chemistry In vivo Cancer Imaging with Semiconductor Quantum Dots
Current Pharmaceutical Analysis Recent Development and SAR Analysis of Colchicine Binding Site Inhibitors
Mini-Reviews in Medicinal Chemistry Collaborative and Defensive Fibroblasts in Tumor Progression and Therapy Resistance
Current Medicinal Chemistry The Epigenetics of Breast Carcinogenesis and Metastasis
Current Genomics Transporter-Based Delivery of Anticancer Drugs to the Brain: Improving Brain Penetration by Minimizing Drug Efflux at the Blood-Brain Barrier
Current Pharmaceutical Design Applicability and Approaches of (Meth) Acrylate Copolymers (Eudragits) in Novel Drug Delivery Systems
Current Drug Therapy Oncolytic Viruses: Programmable Tumour Hunters
Current Gene Therapy Multi-output Model with Box-Jenkins Operators of Quadratic Indices for Prediction of Malaria and Cancer Inhibitors Targeting Ubiquitin- Proteasome Pathway (UPP) Proteins
Current Protein & Peptide Science NOTCH Signaling as a Novel Cancer Therapeutic Target
Current Cancer Drug Targets Understanding the Monoclonal Antibody Involvement in Targeting the Activation of Tumor Suppressor Genes
Current Topics in Medicinal Chemistry The Impact of Translational Research in Breast Cancer Care: Can we Improve the Therapeutic Scenario?
Anti-Cancer Agents in Medicinal Chemistry Smart Triggered Release in Controlled Drug Delivery
Current Drug Targets A Survey on the Usage of Supplements in Canadian Patients Living with HIV
Current HIV Research Imaging Malignant Gliomas with 99mTc-MIBI Brain Single-Photon Emission Computed Tomography
Current Medical Imaging Synthesis and <i>in Vitro</i> Cytotoxicity Evaluation of Phenanthrene Linked 2,4- Thiazolidinediones as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in Application of Poly-Epsilon-Caprolactone and its Derivative Copolymers for Controlled Release of Anti-Tumor Drugs
Current Cancer Drug Targets Targeted Therapy for Advanced Renal Cell Cancer: Cytokines and Beyond
Current Pharmaceutical Design Dual Inhibition of Cdc7 and Cdk9 by PHA-767491 Suppresses Hepatocarcinoma Synergistically with 5-Fluorouracil
Current Cancer Drug Targets Bacterial Biotransformation and Anticancer Activities of Betulin against A549, HepG2 and 5RP7 Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry